Zum Inhalt springen
Home » Gan & Lee Pharmaceuticals to Present Groundbreaking Data

Gan & Lee Pharmaceuticals to Present Groundbreaking Data

A phase 1b/2a trial evaluated once- and bi-weekly GZR18, a novel GLP-1 analog, in Chinese subjects with obesity/overweight
Pre-clinical studies evaluated the molecular and pharmacological properties of GZR4, an investigational once-weekly insulin analog
Pre-clinical studies evaluated and characterized an ultra-long-acting basal insulin, GZR33, and its premixed formulation GZR101